Scholar Rock Holding Corp

$26.19 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Scholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for the treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members. It is channeled for the treatment of diseases, such as tissue and organ fibrosis, bone marrow fibrosis, and other oncologic and hematological disorders.

Stock Analysis

last close $26.19
1-mo return -15.7%
3-mo return -20.8%
avg daily vol. 136.58T
52-week high 70
52-week low 13.31
market cap. $940M
forward pe -
annual div. -
roe -72.6%
ltg forecast -
dividend yield -
annual rev. $16M
inst own. -

Subscribe now for daily local and international financial news